GlassScriptPhysician profile
James J Holton
NPI 1740215938
$44,634.93
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $8,627 · 2021: $6,889 · 2022: $19K · 2023: $7,394 · 2024: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,863 · Food and Beverage: $440 · Travel and Lodging: $56.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,862.50 |
| Food and Beverage | $439.97 |
| Travel and Lodging | $56.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,941.94 | 2021-2024 | |
| Allergan, INC. | $8,200.07 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $965.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $790.78 | 2019-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $594.06 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $410.95 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.77 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $292.57 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $268.40 | 2019-2023 | Evenity, Prolia |
| Pfizer INC. | $265.29 | 2019-2022 | |
| Lilly USA, LLC | $250.01 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $148.17 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $119.18 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $98.70 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.19 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Holton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.